Skip to main content
TipRanks
Go Ultimate75% OFF

Crispr Therapeutics AG (0VRQ) Ownership - Who Owns Crispr Therapeutics AG?

8 Followers

Crispr Therapeutics AG (0VRQ) Ownership Overview

  • 2.60% Insiders
  • 13.66% Mutual Funds
  • 34.23% Other Institutional Investors
  • 22.02% ETFs
  • 27.49% Public Companies and Individual Investors

The ownership structure of Crispr Therapeutics AG (GB:0VRQ) stock is a mix of institutional, retail, and individual investors. Approximately 69.91% of the company’s stock is owned by Institutional Investors, 2.60% is owned by Insiders, and 27.49% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Recent Insider Trading Activity
DateNameActivityValue
Sep 20, 2026Ali Behbahani$780,934
Jan 26, 2026Naimish Patel$49,704

Recent Hedge Fund Trading Activity

Recent Hedge Fund Trading Activity
DateFirmActivityValue
Dec 31, 2025Elkhorn Partners Limited Partnership$87,050
Dec 31, 2025No Street Gp Lp$6,555,000
Dec 31, 2025Ark Investment Management Llc$551,776,669

Top Shareholders

GB:0VRQ top shareholders
Holder# of SharesType% HoldingValue
Cathie Wood10,056,844Institution10.37%426,510,754
Ark9,618,323Institution9.92%407,913,078
BlackRock, Inc.8,299,872Institution8.56%351,997,572
Ishares4,630,393Institution4.77%196,374,967
Spdr3,244,091Institution3.34%137,581,899
Simeon George2,054,249Insider2.12%87,120,700
New Perspective Fund1,944,073Institution2.00%82,448,136
Vanguard1,810,702Institution1.87%76,791,872
Smallcap World Fund Inc1,694,327Institution1.75%71,856,408
Growth Fund Of America1,414,053Institution1.46%59,969,988

Top Mutual Fund Holders

GB:0VRQ top mutual fund holders
Holder# of SharesType% HoldingValue
New Perspective Fund1,944,073Institution2.00%82,448,136
Smallcap World Fund Inc1,694,327Institution1.75%71,856,408
Growth Fund Of America1,414,053Institution1.46%59,969,988
Fidelity Salem Street Trust1,159,051Institution1.19%49,155,353
Vanguard Index Funds1,106,745Institution1.14%46,937,055
T. Rowe Price Mid-cap Growth Fund, Inc.1,050,191Institution1.08%44,538,600
Fidelity Concord Street Trust946,149Institution0.98%40,126,179
Fidelity Mt. Vernon Street Trust861,194Institution0.89%36,523,238
Vanguard Scottsdale Funds631,378Institution0.65%26,776,741
T. Rowe Price Quantitative Management Funds, Inc.351,358Institution0.36%14,901,093

FAQ

Who Owns Crispr Therapeutics AG (GB:0VRQ)?
According to the latest TipRanks data, approximately 69.91% of the company's stock is held by institutional investors, 2.60% is held by insiders, and 27.49% is held by public companies and individual investors.
What percentage of Crispr Therapeutics AG (GB:0VRQ) stock is held by institutional investors?
According to the latest TipRanks data, approximately 69.91% of Crispr Therapeutics AG (GB:0VRQ) stock is held by institutional investors: 13.66% by mutual funds, 22.02% by ETFs and 34.23% by other institutional investors.
What percentage of Crispr Therapeutics AG (GB:0VRQ) stock is held by retail investors?
According to the latest TipRanks data, approximately 27.49% of Crispr Therapeutics AG (GB:0VRQ) stock is held by public companies and individual investors.
Who owns the most shares of Crispr Therapeutics AG (GB:0VRQ)?
Cathie Wood owns the most shares of Crispr Therapeutics AG (GB:0VRQ).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.